Press Releases

Press Releases

Y-mAbs Announces Update on Omburtamab for DIPG

NEW YORK , June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today
Read more
Jun 04, 2021

Y-mAbs Announces Update on SADA Technology

NEW YORK , May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced
Read more
May 13, 2021

Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting

NEW YORK , April 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer is pleased to
Read more
Apr 29, 2021

Y-mAbs Provides Regulatory Update on Omburtamab

NEW YORK , April 20, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today
Read more
Apr 20, 2021

Y-mAbs Announces GPA33-SADA Data Presented at AACR

NEW YORK , April 12, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today
Read more
Apr 12, 2021
Displaying 1 - 10 of 16